Valiant Organics Q1 FY27 Revenue Climbs 13.3% YoY to ₹2,315 Mn, EBITDA Surges 67.7%
Valiant Organics Limited reported Q1-FY27 revenue of ₹2,315 million, up 13.3% YoY. EBITDA surged 67.7% to ₹416 million with margins at 17.97%. PAT increased to ₹293 million, and EPS was ₹10.44. The company highlighted improved margins and operational efficiencies.
The substantial increase in revenue and profitability, coupled with record-high EBITDA margins, is a material positive development for the company's financial health and investor outlook.
The company reported significant year-over-year growth in revenue, EBITDA, and PAT, along with improved margins and EPS, indicating strong financial performance.
Valiant Organics Limited has announced its financial results for the quarter ended June 30, 2026 (Q1-FY27), presenting an investor presentation detailing significant year-over-year growth.
The company reported operational revenue of ₹2,315 million, a 13.3% increase compared to ₹2,044 million in Q1-FY26. This marks the highest quarterly revenue in the last six quarters and signifies a full recovery from the H1 FY26 trough. The company also saw a substantial 67.7% rise in EBITDA, reaching ₹416 million from ₹248 million in the same period last year, with the EBITDA margin expanding to 17.97%, the highest in six quarters.
Gross profit margin improved to 43% from 39% YoY, aided by a reduction in raw material consumption by approximately 410 basis points. Raw material costs decreased to 57% of sales from 61%, resulting in savings of about ₹4 for every ₹100 of revenue. Employee and other expenses increased by only 4.6% YoY, despite the 14% revenue growth, highlighting improved operating efficiency. Finance costs declined by 15% YoY to ₹51 million.
Profit After Tax (PAT) for the quarter was ₹293 million, a significant jump from ₹82 million in Q1-FY26, with PAT margins improving to 12.66% from 4.01% YoY. Basic/Diluted EPS stood at ₹10.44, up from ₹2.93 in the prior year's quarter.
The company's product portfolio spans various chemistries including Chlorination, Hydrogenation, Ammonolysis, and others, serving diverse industries such as Pharmaceuticals, Dyes & Pigments, Agrochemicals, and specialty chemicals. Valiant Organics operates six manufacturing units across five locations, with a total production capacity of 70,000 TPA.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.